Abnormal Glutamate Receptor Expression in the Medial Temporal Lobe in Schizophrenia and Mood Disorders
The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Pharmacological and anatomical evidence suggests that abnormal glutamate neurotransmission may be associated with the pathophysiology of schizophrenia and mood disorders. Medial temporal lobe structural alterations have been implicated in schizophrenia and to a lesser extent in mood disorders. To comprehensively examine the ionotropic glutamate receptors in these illnesses, we used in situ hybridization to determine transcript expression of N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), and kainate receptor subunits in the medial temporal lobe of subjects with schizophrenia, bipolar disorder (BD), or major depression (MDD). We used receptor autoradiography to assess changes in glutamate receptor binding in the same subjects. Our results indicate that there are region- and disorder-specific abnormalities in the expression of ionotropic glutamate receptor subunits in schizophrenia and mood disorders. We did not find any changes in transcript expression in the hippocampus. In the entorhinal cortex, most changes in glutamate receptor expression were associated with BD, with decreased GluR2, GluR3, and GluR6 mRNA expression. In the perirhinal cortex we detected decreased expression of GluR5 in all three diagnoses, of GluR1, GluR3, NR2B in both BD and MDD, and decreased NR1 and NR2A in BD and MDD, respectively. Receptor binding showed NMDA receptor subsites particularly affected in the hippocampus, where MK801 binding was reduced in schiz…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In depressed patients, synaptic plasticity pathways have been shown to be disrupted in the PFC and hippocampi, correlated with α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and NMDA receptor abnormalities [45,46].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [45]
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566 · cited 2×
“Neurotransmission mediated by ionotropic glutamate receptors underlies several forms of synaptic plasticity in the hippocampus, including long-term potentiation (LTP) and depression (LTD) (Bliss and Collingridge, 1993; Isaac et al, 1995; Linden and Connor, 1995; Nicoll and Malenka, 1995; Selig et al, 1995; Bear and Ab…”
BackgroundLOSS OF RECENT MEMORY AFTER BILATERAL HIPPOCAMPAL LESIONS
Scoville, W. B., & Milner, B. (1957) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.20.1.11 · Cited by 7,322
Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., & Seeburg, P. H. (1994) · Neuron · doi:10.1016/0896-6273(94)90210-0 · Cited by 3,535 · cited 2×
“Scale bar: 5 mm. Neuropsychopharmacology containing predominantly NR2B to containing NR2A in response to different stimuli (Monyer et al, 1994; Sheng et al, 1994).”
BackgroundThe Medial Temporal Lobe Memory System
Squire, L. R., & Zola-Morgan, S. (1991) · Science · doi:10.1126/science.1896849 · Cited by 3,282 · cited 1×
“The entorhinal cortex is a crucial component of the medial temporal lobe memory system (Scoville and Milner, 1957; Squire and Zola-Morgan, 1991).”
BackgroundLong-Term Potentiation--A Decade of Progress?
Malenka, R. C., & Nicoll, A. R. A. (1999) · Science · doi:10.1126/science.285.5435.1870 · Cited by 2,729
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
The neuropathology of schizophrenia
Harrison, P. J. (1999) · Brain · doi:10.1093/brain/122.4.593 · Cited by 1,677 · cited 1×
“…in neuronal size, density, and localization in the hippocampus in schizophrenia and BD, and to a lesser extent in major depressive disorder (MDD) (Arnold, 1997; Benes et al, 1998, 1999; Harrison, 1999; Weinberger, 1999; Harrison and Eastwood, 2001; Heckers and Konradi, 2002; Rajkowska, 2002a, b).”
Meta-analysis of regional brain volumes in schizophrenia
Wright, I. C., Rabe-Hesketh, S., Woodruff, P. W. R., David, A. S., Murray, R. M., & Bullmore, E. T. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.16 · Cited by 1,662
Changing subunit composition of heteromeric NMDA receptors during development of rat cortex
Sheng, M., Cummings, J., Roldan, L. A., Jan, Y. N., & Jan, L. Y. (1994) · Nature · doi:10.1038/368144a0 · Cited by 1,377
Pantelis, C., Velakoulis, D., McGorry, P. D., Wood, S. J., Suckling, J., Phillips, L. J., Yung, A. R., Bullmore, E. T., Brewer, W., Soulsby, B., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12323-9 · Cited by 1,310
Cited by
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
Gonzalez-Burgos, G., & Lewis, D. A. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn070 · Cited by 577
Feyissa, A. M., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.10.005 · Cited by 421
NMDA Receptor and Schizophrenia: A Brief History
Coyle, J. T. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs076 · Cited by 410
Lasky‐Su, J., Neale, B. M., Franke, B., Anney, R. J. L., Zhou, K., Maller, J. B., Vasquez, A. A., Chen, W., Asherson, P., Buitelaar, J., et al. (2008) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30867 · Cited by 391
Emerging role of glutamate in the pathophysiology of major depressive disorder
Hashimoto, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.005 · Cited by 381
Synaptic plasticity in depression: Molecular, cellular and functional correlates
Marsden, W. N. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.012 · Cited by 317
Kainate Receptors in Health and Disease
Lerma, J., & Marques, J. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.045 · Cited by 295
The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
Hu, W., MacDonald, M. L., Elswick, D. E., & Sweet, R. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12547 · Cited by 286
Discovering imaging endophenotypes for major depression
Hasler, G., & Northoff, G. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.23 · Cited by 274
Kainate receptors: Pharmacology, function and therapeutic potential
Jane, D. E., Lodge, D., & Collingridge, G. L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.023 · Cited by 274
Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., Caloro, M., Telesforo, C. L., Caltagirone, S. S., Panaccione, I., et al. (2012) · CNS Drugs · doi:10.2165/11634390-000000000-00000 · Cited by 273
Lukić, I., Getselter, D., Ziv, O., Oron, O., Reuveni, E., Koren, O., & Elliott, E. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0466-x · Cited by 273
An excitatory synapse hypothesis of depression
Thompson, S. M., Kallarackal, A. J., Kvarta, M. D., Van Dyke, A. M., LeGates, T. A., & Cai, X. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.03.003 · Cited by 265
The role of GSK‐3 in synaptic plasticity
Peineau, S., Bradley, C., Taghibiglou, C., Doherty, A., Bortolotto, Z. A., Wang, Y. T., & Collingridge, G. L. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.2 · Cited by 263
Physiology and Pathology of Calcium Signaling in the Brain
Kawamoto, E. M., Vivar, C., & Camandola, S. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00061 · Cited by 249
Chen, Y.-J., Zhang, M., Yin, D.-M., Wen, L., Ting, A., Wang, P., Lu, Y.-S., Zhu, X.-H., Li, S.-J., Wu, C.-Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010669107 · Cited by 238
NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia
Snyder, M. A., & Gao, W.-J. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00031 · Cited by 236
A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings
Gogos, A., Sbisa, A. M., Sun, J., Gibbons, A., Udawela, M., & Dean, B. (2015) · International Journal of Endocrinology · doi:10.1155/2015/615356 · Cited by 232
Glutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228
Aleksandrova, L. R., Phillips, A. G., & Wang, Y. T. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160175 · Cited by 228
Brain NMDA Receptors in Schizophrenia and Depression
Adell, A. (2020) · Biomolecules · doi:10.3390/biom10060947 · Cited by 212
Ionotropic Glutamate Receptors & CNS Disorders
Bowie, D. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708784083821 · Cited by 202
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
“…in the kainic acid receptor have been described using ligand binding (Scarr et al. 2005) and in situ hybridization or RT-PCR of mRNA encoding its subunits (Porter et al. 1997; Beneyto et al. 2007) in studies of prefrontal cortex and hippocampus in schizophrenia (Sokolov 1998; Wilson et al. 2006).”
BackgroundMethodExtracellular matrix abnormalities in schizophrenia
Berretta, S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.010 · Cited by 179
Shaltiel, G., Maeng, S., Malkesman, O., Pearson, B., Schloesser, R. J., Tragon, T., Rogawski, M., Gasior, M., Luckenbaugh, D., Chen, G., et al. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.20 · Cited by 173
Machado-Vieira, R., Manji, H. K., & Zarate, C. A. (2009) · The Neuroscientist · doi:10.1177/1073858409336093 · Cited by 171
The role of glutamate on the action of antidepressants
Hashimoto, K. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.013 · Cited by 173
Cherlyn, S. Y. T., Woon, P. S., Liu, J. J., Ong, W. Y., Tsai, G. C., & Sim, K. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.01.002 · Cited by 165
Li, C.-T., Yang, K.-C., & Lin, W.-C. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00767 · Cited by 162
Pehrson, A. L., & Sanchez, C. (2014) · CNS Spectrums · doi:10.1017/s1092852913000540 · Cited by 161
Réus, G. Z., Stringari, R. B., Ribeiro, K. F., Ferraro, A. K., Vitto, M. F., Cesconetto, P., Souza, C. T., & Quevedo, J. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.02.024 · Cited by 159
Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression
Licznerski, P., & Duman, R. S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.057 · Cited by 157
Impaired discrimination learning in mice lacking the NMDA receptor NR2A subunit
Brigman, J. L., Feyder, M., Saksida, L. M., Bussey, T. J., Mishina, M., & Holmes, A. (2008) · Learning & Memory · doi:10.1101/lm.777308 · Cited by 156
Bipolar disorder and mechanisms of action of mood stabilizers
Rapoport, S. I., Basselin, M., Kim, H.-W., & Rao, J. S. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.06.003 · Cited by 155
Pantazopoulos, H., Markota, M., Jaquet, F., Ghosh, D., Wallin, A., Santos, A., Caterson, B., & Berretta, S. (2015) · Translational Psychiatry · doi:10.1038/tp.2014.128 · Cited by 153
Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population
Faye, C., McGowan, J. C., Denny, C. A., & David, D. J. P. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170818095105 · Cited by 152
Catts, V. S., Lai, Y. L., Weickert, C. S., Weickert, T. W., & Catts, S. V. (2016) · Biological Psychology · doi:10.1016/j.biopsycho.2015.10.013 · Cited by 151
Molecular biomarkers of depression
Gururajan, A., Clarke, G. A., Dinan, T. G., & Cryan, J. F. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.011 · Cited by 153
Behan, Á., Byrne, C., Dunn, M. J., Cagney, G., & Cotter, D. R. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.7 · Cited by 145
2‐D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease
English, J. A., Dicker, P., Föcking, M., Dunn, M. J., & Cotter, D. R. (2009) · PROTEOMICS · doi:10.1002/pmic.200900015 · Cited by 144
Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression
Karolewicz, B., Szebeni, K., Gilmore, T., Maciag, D., Stockmeier, C. A., & Ordway, G. A. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008985 · Cited by 143
Disturbed resting state eeg synchronization in bipolar disorder: A graph-theoretic analysis
Kim, D.-J., Bolbecker, A. R., Howell, J., Rass, O., Sporns, O., Hetrick, W. P., Breier, A., & O'Donnell, B. F. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.03.007 · Cited by 141
The role of NMDA receptors in the pathophysiology and treatment of mood disorders
Ghasemi, M., Phillips, C., Trillo, L., Miguel, Z. D., Das, D., & Salehi, A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.08.017 · Cited by 138
Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?
Rao, J. S., Lee, H.-J., Рапопорт, С. И., & Bazinet, R. P. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.31 · Cited by 137
Levite, M. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1193-3 · Cited by 134
Doucet, G. E., Bassett, D. S., Yao, N., Glahn, D. C., & Frangou, S. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17010095 · Cited by 133
A possible negative influence of depression on the ability to overcome memory interference
Shelton, D. J., & Kirwan, C. B. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.08.016 · Cited by 129
Contributions of the d-serine pathway to schizophrenia
Labrie, V., Wong, A. H. C., & Roder, J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.030 · Cited by 129
The Neuroproteomics of Schizophrenia
English, J. A., Pennington, K., Dunn, M. J., & Cotter, D. R. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.031 · Cited by 127
Which clinical and experimental data link temporal lobe epilepsy with depression?
Kondziella, D., Alvestad, S., Vaaler, A., & Sonnewald, U. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04926.x · Cited by 126
Kuppuswamy, P. S., Takala, C. R., & Sola, C. L. (2014) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2014.02.010 · Cited by 125
Deletion of Glutamate Delta-1 Receptor in Mouse Leads to Aberrant Emotional and Social Behaviors
Yadav, R., Gupta, S. C., Hillman, B. G., Bhatt, J. M., Stairs, D. J., & Dravid, S. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032969 · Cited by 123
Guo, X., Hamilton, P. J., Reish, N. J., Sweatt, J. D., Miller, C. A., & Rumbaugh, G. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.223 · Cited by 120
“In support of this idea, GluR1 (GRIA1) has recently been identified as a schizophrenia susceptibility gene (Magri et al, 2006), and mRNA and protein expression of this AMPAR subunit is altered in patients diagnosed with schizophrenia (Beneyto et al, 2007).”
Cholinergic connectivity: it's implications for psychiatric disorders
Scarr, E., Gibbons, A. S., Neo, J., Udawela, M., & Dean, B. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00055 · Cited by 119
In Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric Disorders
Pantazopoulos, H., & Berretta, S. (2016) · Neural Plasticity · doi:10.1155/2016/9847696 · Cited by 119
Depression: Biological markers and treatment
Nedic Erjavec, G., Sagud, M., Nikolac Perkovic, M., Svob Strac, D., Konjevod, M., Tudor, L., Uzun, S., & Pivac, N. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110139 · Cited by 119
Potential roles of zinc in the pathophysiology and treatment of major depressive disorder
Swardfager, W., Herrmann, N., McIntyre, R. S., Mazereeuw, G., Goldberger, K., Cha, D. S., Schwartz, Y., & Lanctôt, K. L. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.03.018 · Cited by 116
Classical Neurotransmitters and Neuropeptides Involved in Major Depression: a Review
Werner, F.-M., & Coveñas, R. (2010) · International Journal of Neuroscience · doi:10.3109/00207454.2010.483651 · Cited by 113
Ma, J., Wang, S., Yu, H., Li, D., Luo, S., Zheng, S., Wan, L., & Duan, K. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.03.026 · Cited by 112
Roles of glutamate signaling in preclinical and/or mechanistic models of depression
Tokita, K., Yamaji, T., & Hashimoto, K. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.016 · Cited by 111
Uezato, A., Meador‐Woodruff, J. H., & McCullumsmith, R. E. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00752.x · Cited by 106
Self-citationKarlsson, R., Tanaka, K., Heilig, M. A., & Holmes, A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.001 · Cited by 107
Freudenberg, F., Celikel, T., & Reif, A. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.005 · Cited by 105
Applications of blood-based protein biomarker strategies in the study of psychiatric disorders
Chan, M. K., Gottschalk, M. G., Haenisch, F., Tomasik, J., Ruland, T., Rahmoune, H., Guest, P. C., & Bahn, S. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.08.002 · Cited by 101
Gratacòs, M., Costas, J., de Cid, R., Bayés, M., González, J. R., Baca‐García, E., de Diego, Y., Fernández‐Aranda, F., Fernández‐Piqueras, J., Guitart, M., et al. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30902 · Cited by 100
Kraguljac, N. V., White, D. M., Hadley, J. A., Visscher, K., Knight, D., ver Hoef, L., Falola, B., & Lahti, A. C. (2016) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.11.015 · Cited by 99
Yue, L., Xiao-lin, H., & Song, T. (2009) · Brain Research · doi:10.1016/j.brainres.2009.01.009 · Cited by 99
Guilarte, T. R., Opler, M., & Pletnikov, M. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2011.11.008 · Cited by 96
Ketamine and other potential glutamate antidepressants
Dutta, A., McKie, S., & Deakin, J. F. W. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.10.028 · Cited by 98
Translational research in bipolar disorder: emerging insights from genetically based models
Chen, G., Henter, I. D., & Manji, H. K. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.3 · Cited by 95
Roalf, D. R., Nanga, R. P. R., Rupert, P. E., Hariharan, H., Quarmley, M., Calkins, M. E., Dress, E. M., Prabhakaran, K., Elliott, M. A., Moberg, P. J., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.258 · Cited by 95
Wijtenburg, S. A., Yang, S., Fischer, B. A., & Rowland, L. M. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.01.007 · Cited by 94
Deregulation of the A-to-I RNA editing mechanism in psychiatric disorders
Silberberg, G., Lundin, D., Navon, R., & Öhman, M. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr461 · Cited by 93
New hypothesis and treatment targets of depression: an integrated view of key findings
Cai, S., Huang, S., & Hao, W. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-014-1486-4 · Cited by 95
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
“As regards specific glutamate receptors and subunits, reduced NMDAR binding and expression have also been found in individuals with MDD (Beneyto et al., 2007, Choudary et al., 2005, Law and Deakin, 2001, McCullumsmith et al., 2007, Nudmamud-Thanoi and Reynolds, 2004, Toro and Deakin, 2005).”
BackgroundNovel glutamatergic drugs for the treatment of mood disorders
Murrough, J., Lapidus, K., & Soleimani, L. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36689 · Cited by 92
Chan, M. K., Tsang, T. M., Harris, L. W., Guest, P. C., Holmes, E. C., & Bahn, S. (2010) · Molecular Psychiatry · doi:10.1038/mp.2010.100 · Cited by 94
The PSD-95/nNOS complex: New drugs for depression?
Doucet, M. V., Harkin, A., & Dev, K. K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.005 · Cited by 96
An update on the role of glutamate in the pathophysiology of depression
Mitchell, N. D., & Baker, G. B. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01529.x · Cited by 91
Novel antidepressant drugs: Beyond monoamine targets
Gonda, X., Döme, P., Neill, J. C., & Tarazi, F. I. (2021) · CNS Spectrums · doi:10.1017/s1092852921000791 · Cited by 91
Amidfar, M., Woelfer, M., Réus, G. Z., Quevedo, J., Walter, M., & Kim, Y.-K. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109668 · Cited by 90
Ng, W. X. D., Lau, I. Y., Graham, S., & Sim, K. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.10.001 · Cited by 92
Epigenetic mechanisms in schizophrenia
Akbarian, S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.3/sakbarian · Cited by 88
Kristiansen, L. V., Patel, S. A., Haroutunian, V., & Meador‐Woodruff, J. H. (2010) · Synapse · doi:10.1002/syn.20754 · Cited by 86
Self-citationZahr, N. M., Mayer, D., Pfefferbaum, A., & Sullivan, E. V. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhm250 · Cited by 86
Carty, N., Xu, J., Kurup, P., Brouillette, J., Goody, S. M. G., Austin, D. R., Yuan, P., Chen, G., Correa, P. R., Haroutunian, V., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.63 · Cited by 85
Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia
Kraguljac, N. V., Reid, M. A., White, D. M., den Hollander, J., & Lahti, A. C. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.126 · Cited by 84
Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia
Junqueira, D. G., Falvella, A. C. B., Antunes, A. S. L. M., Seabra, G., Brandão‐Teles, C., Martins‐de‐Souza, D., & Crunfli, F. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00379 · Cited by 84
Musazzi, L., Treccani, G., & Popoli, M. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00060 · Cited by 83
Glutamate Receptor Abnormalities in Schizophrenia: Implications for Innovative Treatments
Rubio, M. D., Drummond, J. B., & Meador-Woodruff, J. H. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.1.001 · Cited by 83
Self-citationMolecular signature of extracellular matrix pathology in schizophrenia
Pantazopoulos, H., Katsel, P., Haroutunian, V. H., Chelini, G., Klengel, T., & Berretta, S. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.15009 · Cited by 84
Rass, O., Krishnan, G., Brenner, C. A., Hetrick, W. P., Merrill, C. C., Shekhar, A., & O’Donnell, B. F. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00871.x · Cited by 82
Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?
Fitzgerald, P. J., Barkus, C., Feyder, M., Wiedholz, L. M., Chen, Y.-C., Karlsson, R.-M., Machado-Vieira, R., Graybeal, C., Sharp, T., Zarate, C., et al. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.08.005 · Cited by 80
Holz, A., Mülsch, F., Schwarz, M. K., Hollmann, M., Döbrössy, M. D., Coenen, V. A., Bartos, M., Normann, C., Biber, K., van Calker, D., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.07.011 · Cited by 79
Barbon, A., Caracciolo, L., Orlandi, C., Musazzi, L., Mallei, A., Via, L. L., Bonini, D., Mora, C., Tardito, D., Gennarelli, M., et al. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.07.013 · Cited by 74
Eriksson, T. M., Delagrange, P., Spedding, M., Popoli, M., Mathé, A. A., Ögren, S. O., & Svenningsson, P. (2012) · Molecular Psychiatry · doi:10.1038/mp.2010.131 · Cited by 73
Lithium as a Neuroprotective Agent for Bipolar Disorder: An Overview
Ochoa, E. L. M. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01129-9 · Cited by 74
Corticotropin-Releasing Hormone, Glutamate, and γ-Aminobutyric Acid in Depression
Gao, S.-F., & Bao, A.-M. (2011) · The Neuroscientist · doi:10.1177/1073858410361780 · Cited by 72
Marsden, W. N. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.06.021 · Cited by 73
Metadata
- Authors
- Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H.
- Affiliations
- University of Alabama at Birmingham (US)
- Venue
- Neuropsychopharmacology
- Published
- 2007-02-14
- Volume
- 32
- Issue
- 9
- Pages
- 1888-1902
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2024278554
- Cited by
- 408
- References
- 115
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 12 · 2023: 15 · 2022: 32 · 2021: 26 · 2020: 22 · 2019: 19 · 2018: 10 · 2017: 13 · 2016: 18 · 2015: 32 · 2014: 23 · 2013: 25 · 2012: 28
- FWCI
- 16.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Stanley Medical Research Institute
- National Institute of Mental Health (MH 53327, R01MH053327)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- glutamate receptors, schizophrenia, bipolar disorder, major depressive disorder, mood disorders, medial temporal lobe, entorhinal cortex, perirhinal cortex, hippocampus, NMDA receptor, AMPA receptors, kainate receptors, receptor binding, glutamatergic neurotransmission, synaptic transmission
- MeSH terms
- Adult, Analysis of Variance, Autoradiography, Female, Gene Expression Regulation, Humans, Indoles, Male, Middle Aged, Postmortem Changes, Protein Binding, Schizophrenia, Temporal Lobe, 2-Amino-5-phosphonovalerate, In Situ Hybridization, Receptors, Glutamate, Excitatory Amino Acid Antagonists, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.